Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized withdrawal study of ampreloxetine for symptomatic neurogenic orthostatic hypotension
2018-003941-41Phase 3Unknown
- Sponsor
- Theravance Biopharma, Inc.
- Start
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ampreloxetine in Neurogenic Orthostatic Hypotension (nOH) (3 arms), sponsored by Theravance Biopharma, Inc. Primary endpoint: Proportion of treatment failure at Week 6 during the double-blind randomized withdrawal phase. Status: unknown.
02
Drugs
ampreloxetine
03
Conditions
Neurogenic Orthostatic Hypotension (nOH)
Beyond the preview
Go deeper on 2018-003941-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003941-41.